Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Hybio Pharmaceutical Grants Wansheng Pharmaceutical Exclusive China License for Semaglutide’s Glycemic Control Indication in Up-to-RMB 182.5 Million Deal

Fineline Cube Aug 13, 2026
Company Deals

Insilico Medicine and THPharma Launch AI Research Collaboration to Build ‘Reverse Translation’ Drug Discovery Strategy Around Phase 3 Candidate THP-001

Fineline Cube Aug 13, 2026
Company Deals

Zhaoke Ophthalmology Signs Exclusive Distribution and Promotion Agreement With Pengpai Bio for Epinastine Hydrochloride Eye Drops in Mainland China

Fineline Cube Aug 13, 2026
Company Deals

Allist Pharmaceuticals Secures Exclusive Greater China License for ArriVent’s Bispecific ADC AST12608/ARR-002

Fineline Cube Aug 13, 2026
Company Deals

Kintor Pharmaceutical Grants Wellrise Exclusive Distribution Rights for KT-939 Raw Material in South Korea

Fineline Cube Aug 13, 2026
Policy / Regulatory

China’s CDE Releases 109th Reference Listed Drug Catalog, Adding 10 New Generic Drug Specifications

Fineline Cube Aug 6, 2026
Company Drug

Ark Biopharmaceutical’s First-in-Class AFC AK0406 Wins NMPA Approval for Influenza Prevention Clinical Trials

Fineline Cube Aug 13, 2026
Company Drug

Youcare Pharmaceutical’s YKYY033 siRNA Injection Wins US FDA Approval to Conduct Clinical Trials for Arterial and Venous Thrombosis

Fineline Cube Aug 13, 2026
Company Drug

Jacobio Pharma Doses First Patient in US Phase I/IIa Study for JAB-2485

Fineline Cube Jan 9, 2023

China-based Jacobio Pharma (HKG: 1167) has announced that the first patient has been dosed in...

Company Deals

VACSERA in Talks with Sinovac to Establish Integrated Vaccine Plant

Fineline Cube Jan 9, 2023

Egypt-based drug firm Holding Company for Biological Products and Vaccines (VACSERA) is reportedly in talks...

Company Drug

Eisai CEO Outlines Ambitions for Alzheimer’s Drug Leqembi After FDA Approval

Fineline Cube Jan 9, 2023

Following US FDA approval for Japan-based Eisai Co., Ltd (TYO: 4523) and Biogen Inc’s (NASDAQ:...

Company Drug

Dizal’s Sunvozertinib and Golidocitinib Combo Gets NMPA Approval for Phase II Study

Fineline Cube Jan 9, 2023

China-based Dizal Pharmaceutical Co., Ltd (SHA: 688192) has announced receiving approval from the National Medical...

Company Drug

Luye Pharma’s BA1301 Receives CDE Approval for Clinical Trials

Fineline Cube Jan 9, 2023

China-based Luye Pharma Group (HKG: 2186) has announced receiving clinical trial approval from the Center...

Policy / Regulatory

China’s National Health Commission Releases Updated COVID-19 Treatment Plan

Fineline Cube Jan 9, 2023

The National Health Commission (NHC) has released the 10th edition of the national COVID-19 Diagnosis...

Company Drug

HutchMed’s Sovleplenib Administered to First Patient in Phase II COVID-19 Study

Fineline Cube Jan 6, 2023

On January 4, Hutchison China Meditech (HutchMed; HKG: 0013, NASDAQ: HCM) administered its novel, investigational,...

Company Medical Device

Zai Lab and Novocure’s TTFields Device Shows Survival Benefit in Lung Cancer Study

Fineline Cube Jan 6, 2023

Shares in Chinese firm Zai Lab Ltd (NASDAQ: ZLAB, HKG: 9688) and its partner Novocure...

Company Drug

Salubris Pharmaceuticals Gains NMPA Approval for Phase I Study of SAL0133

Fineline Cube Jan 6, 2023

China’s Shenzhen Salubris Pharmaceuticals Co., Ltd (SHE: 002294) has announced receiving approval from the National...

Company Deals

Kactus Biosystems Partners with Bioheng for Cell Therapy Raw Materials

Fineline Cube Jan 6, 2023

Shanghai-based Kactus Biosystems, a firm specializing in target proteins and raw enzymes, has announced a...

Company Deals

Immune-Onc Therapeutics Completes $131 Million Series B Financing

Fineline Cube Jan 6, 2023

US-headquartered Immune-Onc Therapeutics, Inc. has announced the successful completion of a Series B financing round...

Company Drug

Henlius Completes First Dosing in Global Phase III Study for HanSiZhuang in LS-SCLC

Fineline Cube Jan 6, 2023

Shanghai Henlius Biotech (HKG: 2696) has announced the completion of the first subject dosing in...

Company Deals

Singular Medical Secures Series B+ Funding for Cardiac Device Development

Fineline Cube Jan 6, 2023

Singular Medical, a Suzhou-based maker of cardiac rhythm and heart failure devices, has reportedly raised...

Company Drug

Boehringer Ingelheim Enrolls First Patient in Phase II/III Study for BI 907828

Fineline Cube Jan 6, 2023

German pharmaceutical giant Boehringer Ingelheim has announced the enrollment of the first patient in the...

Company Drug

Vcanbio’s Stem Cell Therapy VUM02 Accepted for Clinical Trial Review

Fineline Cube Jan 6, 2023

China-based Vcanbio Cell & Gene Engineering Corp., Ltd (SHA: 600645) has announced that the clinical...

Company Drug

CanSino Biologics’ mRNA Vaccine CS-2034 Shows Positive Safety and Immunogenicity Data

Fineline Cube Jan 6, 2023

China-based CanSino Biologics (HKG: 6185) has announced positive periodical data from a clinical study assessing...

Company Deals

Mindray Partners with BOMImed for Exclusive Canadian Sales and Service

Fineline Cube Jan 6, 2023

China-based medical device giant Mindray’s North American unit has announced a partnership with Canadian biomedical...

Company Deals

Simnova Partners with Orna Therapeutics for In Situ CAR Therapies

Fineline Cube Jan 6, 2023

Shanghai Simnova Biotech Co., Ltd. (Simnova), an affiliate of Simcere Investment Group, has announced a...

Company

Aurisco Partners with Cytiva to Build Oligonucleotide Production Plant

Fineline Cube Jan 6, 2023

China-based contract development and manufacturing organization (CDMO) Aurisco Pharmaceutical Co., Ltd has revealed plans to...

Company Drug

Jiangsu Aidea’s ACC007 Approved by NMPA for HIV-1 Treatment

Fineline Cube Jan 5, 2023

China-based Jiangsu Aidea Pharmaceutical Co., Ltd (SHA: 688488) has announced that its Category 1 compound...

Posts pagination

1 … 619 620 621 … 708

Recent updates

  • Hybio Pharmaceutical Grants Wansheng Pharmaceutical Exclusive China License for Semaglutide’s Glycemic Control Indication in Up-to-RMB 182.5 Million Deal
  • Insilico Medicine and THPharma Launch AI Research Collaboration to Build ‘Reverse Translation’ Drug Discovery Strategy Around Phase 3 Candidate THP-001
  • Ark Biopharmaceutical’s First-in-Class AFC AK0406 Wins NMPA Approval for Influenza Prevention Clinical Trials
  • Youcare Pharmaceutical’s YKYY033 siRNA Injection Wins US FDA Approval to Conduct Clinical Trials for Arterial and Venous Thrombosis
  • AstraZeneca and Daiichi Sankyo’s Enhertu Wins China Approval for First-Line HER2-Positive Metastatic Breast Cancer in Combination With Pertuzumab
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Hybio Pharmaceutical Grants Wansheng Pharmaceutical Exclusive China License for Semaglutide’s Glycemic Control Indication in Up-to-RMB 182.5 Million Deal

Company Deals

Insilico Medicine and THPharma Launch AI Research Collaboration to Build ‘Reverse Translation’ Drug Discovery Strategy Around Phase 3 Candidate THP-001

Company Drug

Ark Biopharmaceutical’s First-in-Class AFC AK0406 Wins NMPA Approval for Influenza Prevention Clinical Trials

Company Drug

Youcare Pharmaceutical’s YKYY033 siRNA Injection Wins US FDA Approval to Conduct Clinical Trials for Arterial and Venous Thrombosis

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.